SCHEMBL25600532

SCHEMBL25600532

CC(C)C(=O)N1CCC(N2CC3(CC(N4CC5(CC(C(C)C)C5)C4)C3)C2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HRH3 Q9Y5N1 4/20 0.34
▸ CHRM1 P11229 2/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL3 Q96JM7 4/20 0.32
▸ L3MBTL1 Q9Y468 3/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ MBTD1 Q05BQ5 1/20 0.31
▸ TP53BP1 Q12888 1/20 0.31
▸ L3MBTL4 Q8NA19 1/20 0.31
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNA3 P32297 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31
▸ CHRNB3 Q05901 1/20 0.31
▸ CHRNA6 Q15825 1/20 0.31
▸ OPRL1 P41146 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25600531 0.94 CHRM1 (0.38) CYP3A4CYP2C19HRH3CHRM1CHRM2
SCHEMBL25600528 0.92 HRH3 (0.37) CYP3A4CYP2C19HRH3CHRM1CHRM2
SCHEMBL25600527 0.92 OPRL1 (0.38) CYP3A4CYP2C19HRH3CHRM1CHRM2
SCHEMBL25605740 0.87 KDM4E (0.35) CYP3A4CYP2C19HRH3MEN1ALDH1A1
SCHEMBL25605744 0.85 ALDH1A1 (0.45) CYP3A4CYP2C19HRH3CHRM1CHRM2
SCHEMBL25600526 0.83 OPRL1 (0.34) HRH3CHRM1CHRNB2CHRNA3CHRNA4
SCHEMBL25600327 0.83 OPRL1 (0.36) HRH3CHRM1CHRM2OPRL1
SCHEMBL25600565 0.83 HRH3 (0.34) HRH3CHRM1MEN1KMT2AL3MBTL3
SCHEMBL25605724 0.82 CHRM4 (0.39) HRH3CHRM1MEN1KMT2AOPRL1
SCHEMBL25605729 0.82 HRH3 (0.36) HRH3MEN1KMT2AL3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 CYP3A4 2211/4885CYP2C19 3201/4885HRH3 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback